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To identify the genomic regions that confer risk and protection for major depressive disorder (MDD) in
humans, large-scale studies are needed. Such studies should collect multiple phenotypes, DNA, and ideally,
biological material that allows gene expression analysis, transcriptomic, proteomic, and metabolomic
studies. In this paper, we briefly review linkage studies of MDD and then describe the large-scale
nationwide biological sample collection in Dutch twin families from the Netherlands Twin Register (NTR)
and in participants in the Netherlands Study of Depression and Anxiety (NESDA). Within these studies,
1862 participants with a diagnosis of MDD and 1857 controls at low liability for MDD have been selected
for genome-wide genotyping by the US Foundation for the National Institutes of Health Genetic
Association Information Network. Stage 1 genome-wide association results are scheduled to be accessible
before the end of 2007. Genome-wide association results are open-access and can be viewed at the dbGAP
web portal (http://www.ncbi.nlm.nih.gov). Approved users can download the genotype and phenotype
data, which have been made available as of 9 October 2007.
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Introduction
The defining features of major depressive disorder (MDD)
are marked and persistent depressed mood, associated
with physical and cognitive signs and symptoms (anhedonia,
insomnia or hypersomnia, appetite and weight
changes, psychomotor agitation or retardation, fatigue or
loss of energy, excessive guilt or worthlessness, poor
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concentration or indecisiveness, and recurrent thoughts of
death or suicide). MDD is distinct from ‘normal’ sadness by
its persistence (ie, Z2 weeks), the presence of accompany-
ing signs and symptoms, and its associated impairment.
The definition of MDD excludes other disorders that can
have substantial depressive symptoms. These include
bipolar disorder, schizophrenia, schizoaffective disorder,
and depressive symptoms resulting from another disorder
(eg, medical condition like hypothyroidism).1
Combining available estimates, the lifetime prevalence
of MDD is B15% and is twofold higher in women than
in men.2 The course of MDD is typified by recurrence of
illness. In a meta-analysis, 76% had Z1 recurrence over a
10-year follow-up.3 MDD is associated with large morbidity
(greater than chronic medical conditions such as diabetes
and arthritis),4 – 6 excess mortality from suicide and other
causes,7 – 10 and substantial direct and indirect costs (4$43
billion/year in the US).11 The WHO projected MDD to be
the second leading cause of disability worldwide by 2020.12
Thus, MDD is a first-rank public health problem.
It has been firmly established that variation in MDD
liability is in part genetic.13 Family studies find a
significantly higher lifetime prevalence of MDD in biolo-
gical relatives of MDD probands (pooled odds ratio¼2.84,
95% CI¼2.31–3.49). Twin studies have established that
the familial component reflects genetic vulnerability rather
than shared environmental risk. The meta-analytic herit-
ability estimate is 37% (95% CI¼ 31–42%) with a minimal
contribution of environmental effects common to siblings
(0, 95% CI¼0–5%), and substantial individual-specific
environmental effects/measurement error (63, 95%
CI¼58–67%).
Despite the evidence for heritability of MDD, as with
most complex traits, identification of vulnerability genes
has not been yet very successful. Results from studies of
first-stage genome-wide linkage scans for MDD or related
personality traits are summarized in Figure 1. One study
was of MDD,14 two of recurrent MDD,15,16 and three of
recurrent, early-onset MDD.17 – 19 Five studies investigated
quantitative traits related to MDD, that is harm avoid-
ance20 and neuroticism.21 – 24 Two studies were secondary
analyses of cohorts selected for alcoholism14 or nicotine
dependence.23
Results from linkage studies of MDD and associated
personality traits are summarized in Figure 1. Regions on
chromosomes 1, 4, 5, 7, 8, 11, 12, and 13 show a significant
linkage signal (LOD43) in at least one study. However,
taken together these studies do not indicate a large degree
of replication. This lack of success so far, may be due to
the relatively small sample sizes of most linkage studies.
Likewise, the generally small sizes, the different definitions
of the phenotype, and the limited number of polymorphisms
that could be included in association studies of candidate
genes have not lead to consistent results. This is even true
for candidate genes that have been assessed in large sized
studies.25 – 27
However, since 2000 there have been exceptional
advances in our knowledge of the human genome along
with a precipitous drop in the cost of genotyping. These
advances directly led to genome-wide association studies
whereby large case–control samples are individually
genotyped for 500 000 or more single nucleotide poly-
morphisms. Examples where genome-wide association
studies has provided new genetic insights include the
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Figure 1 First-stage genome-wide linkage scans for MDD or related personality traits (neuroticism and harm-avoidance). The x-axis shows the
human genome from 1ptel to 22qtel. Each row shows the findings for that study. Studies of bipolar disorder, candidate region linkage studies, fine-
mapping results, and statistical analyses of epistasis or studies that included covariate models were excluded. The width of the coloured bars indicates
the genomic physical distance/region implicated by a particular study. LOD/equivalents are plotted. Key: red LODZ3, green LODZ2, blue LODZ1.5,
grey otherwise.
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CFH gene and age-related macular degeneration,28 the FTO
gene and body mass index in children and adults,29 the
TCF7L2 gene and type-2 diabetes30 and the IL23R gene
and inflammatory bowel disease.31 Recently, the Wellcome
Trust Case Control Consortium32 identified 24 association
signals for seven major diseases, including bipolar disorder,
using 2000 cases and 3000 controls.
In 2006, a consortium of investigators at the VU
University Amsterdam, universities in Groningen and
Leiden, and UNC-Chapel Hill in the US was selected for
GWA genotyping as one of the six Genetic Association
Information Network (http://www.fnih.org/GAIN) studies.33
The GAIN initiative is a component of the public–
private partnership of the Foundation for the National
Institutes of Health Inc., and funding is via Pfizer,
Affymetrix, and Abbott Laboratories. GWA genotyping for
600 000 single nucleotide polymorphisms in MDD cases
and population-based controls has been conducted by
Perlegen Sciences. Stage 1 genome-wide association results
are scheduled to be available before the end of 2007 and
will be available to the scientific community via the
NCBI dbGAP web portal (http://www.ncbi.nlm.nih.gov).
Approved users can download genotype and phenotype
data with the restriction that use of genotype and
phenotype data is restricted to psychiatric health and
related somatic conditions.
In this paper, we describe the approach and logistics of
the two large-scale projects in the Netherlands collecting
biological samples for genetic studies, which together
constitute the GAIN-MDD study. We give an overview of
the phenotyping for MDD and the selection of case and
control subjects for GWA genotyping in the GAIN-MDD
study.
Subjects
Subjects eligible for inclusion in the GWA study of MDD
come from two large longitudinal projects: 1702 depressed
cases come from the Netherlands Study of Depression
and Anxiety (NESDA, www.nesda.nl), and 1700 controls
come from the Netherlands Twin Registry (NTR, www.
tweelingenregister.org). In addition, 160 cases from the
NTR and 157 controls from the NESDA study were included
in the original selection, and both parents of 33 controls to
form 33 trios and 21 duplicate samples.
MDD cases
Depressed subjects (cases) are mainly derived from NESDA,
a longitudinal cohort study designed to be representative
of those with depression and anxiety disorders in different
health care settings and in different stages of the develop-
mental history of the disorders. Details on objectives,
recruitment, and methods of NESDA have been described
elsewhere.34 In short, recruitment of participants took
place from September 2004 through February 2007. Cases
from mental health care organizations were recruited from
seven outpatient regional facilities in the Netherlands
(total catchment area¼1 175 000 persons). When new
patients were diagnosed with a depressive and/or anxiety
disorder during a standardized intake assessment, they
were asked to participate in NESDA. For recruitment of
respondents in primary care, a three-stage screening
procedure was used. A random sample of patients who
consulted a GP in the last 4 months, irrespective of the
reason for consultation, filled out a screening question-
naire.35 Those who screened positive were interviewed by
phone with the short-form of the Composite International
Diagnostic Interview (CIDI).36 Those with current MDD or
an anxiety disorder were asked to participate in NESDA and
were invited for a baseline assessment, which included a
full CIDI interview. A community sample of NESDA cases
was derived from the Netherlands Mental Health Survey
and Incidence Study, a community-based study examining
the prevalence of psychiatric disorders in the Netherlands.37
A multistage, stratified, random sampling procedure
recruited 7076 respondents from different households in
90 Dutch municipalities. Those who were diagnosed with
lifetime MDD or anxiety disorder during one of the CIDI
interviews in 1996, 1997 or 1999, were approached for
participation in NESDA. Finally, the NESDA sample
includes a subgroup previously recruited for the Adoles-
cents at Risk for Anxiety and Depression Study,38 a
prospective cohort study examining the development and
course of MDD and anxiety disorders among the offspring
(18–25 years) of parents with depressive or anxiety
disorders. Potential cases in the NTR were identified based
on a multivariate composite score that combined survey
data on depression, anxiety, and neuroticism.39 From this
group of potential cases, we selected unrelated subjects,
who received a CIDI interview by telephone.
Regardless of recruitment setting, similar inclusion, and
exclusion criteria were used to select MDD cases. Inclusion
criteria were a lifetime diagnosis of DSM-IV MDD as
diagnosed through the CIDI psychiatric interview (section
E, version 2.1), an age between 18 and 77 years and self-
reported western European ancestry. Persons who were not
fluent in Dutch and those with a primary diagnosis of
a psychotic disorder, obsessive compulsive disorder,
bipolar disorder, or severe substance use dependence were
excluded. The 1862 cases included in GAIN, were recruited
through mental health care organizations (785), primary
care practitioners (603), and community samples (218
Netherlands Mental Health Survey and Incidence Study, 96
Adolescents at Risk for Anxiety and Depression Study and
160 NTR).
Control subjects
Control subjects are mainly derived from the NTR, which
has collected longitudinal data by mailed surveys every
2–3 years since 1991. Data collection has occurred in 1991,
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1993, 1995, 1997, 2000, 2002/3, and 2004/5 and takes
place in twins and their family members. There are nearly
22 000 participants from 5546 families (some families are
linked and come from larger pedigrees). The majority of
families were recruited when the twins were young adults
through City Council registration systems in 1990–91 and
in 1992–93. After 1993 an effort was made to recruit adult
and older twins through a variety of approaches. Details on
recruitment, response rates, response bias, and demo-
graphic characteristics of the sample have been described
previously.40 The sex distribution is 40% men and 60%
women for twins, 45 and 55% for the siblings of twins,
47 and 53% for parents, and 64 and 36% for spouses.
Longitudinal phenotyping by survey includes assessment
of depressive symptoms (multiple instruments), anxiety,
neuroticism, and other personality measures. Additionally,
subjects are asked about life events, lifestyle, education,
health, and religious background.
From the group of NTR participants for whom both
survey data and biological samples were available, we
selected controls for the MDD cases. Controls never scored
high (40.65) on a general factor score for anxious
depression. The factor score is a combined measure of
neuroticism, anxiety, and depressive symptoms assessed
via longitudinal questionnaires.39 It has a mean of 0 and a
SD of 0.7. Subjects never reported a history of MDD in any
survey or at the blood sampling visit (either as a complaint
for which treatment was sought from a specialist, reported
medication use, or via the CIDI). Controls and their
parents were born in the Netherlands or western Europe.
If there were multiple eligible controls in a family, we first
matched on sex and age, and used the highest number of
completed questionnaires as an additional criterion. Only
biologically unrelated subjects were selected.
The NESDA controls (133 from general practice, 24 from
Adolescents at Risk for Anxiety and Depression Study)
came from a larger healthy control group. Controls did not
have a lifetime diagnosis of MDD or an anxiety disorder
as assessed by the CIDI, and all controls reported low
depressive symptoms at baseline (o16 on K-10 (29),ofour
on Inventory of Depressive Symptoms41).
IRB approvals and informed consent
The NESDA and NTR studies were approved by the Central
Ethics Committee on Research involving human subjects
of the VU University Medical Center, Amsterdam, an
Institutional Review Board certified by the US Office of
Human Research Protections (IRB number IRB-2991 under
Federal wide Assurance-3703; IRB/institute codes, NESDA
03-183; NTR 03-180). All subjects provided written in-
formed consent. As part of the GAIN application process,
consent forms were re-reviewed. For NESDA, only 22
respondents refused informed consent for genetic research
(1.7% of all respondents approached). NTR participants
were approached with a broad consent form for the entire
NTR biobank project.
Phenotyping
MDD, depressive symptoms, and other
psychopathology indicators
NESDA The Composite International Diagnostic Inter-
view, section E, version 2.136 was used to diagnose MDD.
The interview also provides information on age of onset,
number of episodes of MDD, and specific symptoms of
depression. Information on lifetime comorbid panic dis-
order with or without agoraphobia, generalized anxiety
disorder, social phobia, alcohol use, and dependence was
also collected with the CIDI. Depression and anxiety
severity indicators include the Inventory of Depressive
Symptoms-self-report (IDS-SR41), the Fear Questionnaire42
and the Beck Anxiety Inventory.43 Neuroticism, an en-
dophenotype for MDD, was assessed with the NEO.44 The
family tree inventory was used to examine depression in
first degree relatives.
NTR Phenotyping for depression in the NTR survey
studies took place with the Beck depression inventory
(BDI45) in 1993 and 1997 and with the depression scale
from the YASR46 in 1991, 1995, 1997, and 2000. Neuroti-
cism was assessed with the ABV47 in five out of six surveys
(not in 1995) and with the NEO44 in 2004. Anxiety (STAI48)
was assessed at five out of seven surveys (not in 1995 and
2004). NTR cases and a subsample of controls underwent
the CIDI protocol by phone; either as part of an earlier
study49 on the heritability of major depression and anxiety
disorders or as part of the selection procedure for GAIN.
Biobank procedures and DNA isolation
Before the start of the NESDA and NTR biological sample
collection, processing and storage protocols were harmo-
nized. Blood sampling for the NESDA participants took
place during the baseline visit and was done between
0830–0930 h at one of the seven field sites, all at walking
distance of laboratories facilities for immediate processing.
For NTR, biological samples were taken at the respondents’
home between 0700 and 1000 h. Starting in 2004, adult
participants registered with the NTR were invited by
letter to participate in a project in which blood and
morning urine samples would be collected. Eligible
participants were Z18 years, had returned at least one
survey or came from a family in which at least one person
completed a questionnaire. The letter was followed by a
telephone call to schedule an appointment for a home
visit. With fertile women, an appointment was made for
the third to fifth day of the menstrual cycle when possible.
For women taking oral contraceptives, an appointment
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was made for their pill-free week. In twin individuals,
we also took buccal swabs for DNA isolation50 as blood
group chimerism in twins is not rare.51 Tubes were stored,
as appropriate, in melting ice (0–21C) during transport, at
room temperature, or in an insulated box with a constant
temperature of 371C. Effects of transportation and storage
on blood quality, RNA with and without challenge,
lymphocytes and other parameters were examined in a
pilot project52 and appear to be negligible.
All venous blood samples were taken after overnight
fasting using a safety-lock butterfly needle. For NESDA
participants, a total of 10 blood tubes were drawn in the
following order: 37 ml and 12 ml EDTA, 27 ml and
12 ml Heparin, 14.5 ml CTAD, 12 ml NaF, and
16 ml ACD. For the NTR participants, a total of seven
blood tubes were drawn in the following order: 29 ml
EDTA, 29 ml Heparin, 1 4.5 ml CTAD, 17 ml serum,
and 12 ml EDTA. For DNA isolation blood collected in
the EDTA anticoagulant tubes was used. For DNA isolation
of NESDA samples the Qiagen FlexiGenes DNA AGF3000
Kit for large volumes of fresh whole human blood was used
on an AutoGenFlex 3000 workstation (Autogen, Holliston,
MA, USA). The GENTRA Puregenes DNA isolation kit
(manual) was used on frozen whole blood samples of the
NTR. DNA concentrations were determined using the
PicoGreens dsDNA Quantitation kit from Molecular
Probes. All procedures were performed according to the
manufacturer’s protocols.
GAIN sample
For the case and the control groups we selected unrelated
subjects. Baseline characteristics of cases and controls, and
of an additional NTR comparison group, are summarized in
Tables 1 and 2. Tables 1 and 2 describe the data as deposited
on the dBGaP website (www.ncbi.nlm.nih.gov/dbgap,
9 October 2007). After excluding subjects with genotyping
or sample problems, data from 1821 MDD cases and 1822
controls are available for analyses. The actual numbers
for genome-wide association analyses may turn out to be
slightly smaller, as extra analyses of the genotype data
may lead to removal of additional subjects. For both MDD
cases and for controls there is information available on the
website about demographics, personality traits (eg, neuro-
ticism), and lifestyle (eg, smoking and alcohol use). The
phenotype information for NESDA respondents is at
present mainly from the baseline interview data. The
baseline interview took 4 h on average and consisted of
the CIDI, a series of self-report questionnaires, a medical
interview, and a fasting blood draw. For NTR respondents,
a total of up to seven surveys were mailed to the
participating twin families over a period of 15 years. NTR
respondents who took part in the biobank protocol were
Table 1 Characteristics of MDD cases by setting and total MDD group
MDD cases by setting Total MDD cases
Community N¼446a Primary care N¼772 Mental health care N¼603 N¼1821
Age (years) 41.2±13.9 45.9±11.7 37.9±11.4 42.1±12.7
Female, % 72.0 72.3 64.7 69.7
Educational level (% low/middle/high) 7.6/62.7/29.6 7.0/54.5/38.5 8.1/66.2/25.8 7.5/60.4/32.1
With partner, % 72.5 69.8 63.8 68.5
Smoking (current), % 40.1 39.2 47.3 42.1
Alcohol use (last year), % 63.7 67.5 66.7 66.3
NEO neuroticism score 35.8±8.1 38.6±8.0 42.7±6.6 39.3±8.0
Family history of MDD, % yes 89.2 85.0 83.6 85.4
Depression; age of onset 26.8±12.5 29.1±12.7 25.8±11.6 27.5±12.3
IDS depressionb 17.2±11.3 23.8±12.1 33.0±12.7 25.8±13.5
BAI anxietyb 8.2±7.5 13.2±9.4 18.9±11.5 14.3±10.6
For continuous traits, the mean score and SD are listed.
aCommunity cases (446): 214 from NEMESIS, 95 from ARIADNE, 137 from NTR.
bSymptom scores are assessed at study baseline, which does not always equal the period of MDD episode.
Table 2 Characteristics of NTR comparison sample and
GAIN controls
NTR comparison
sample N¼4111
GAIN controls
N¼1822a
Age (years) 43.6±15.3 45.1
years±14.1
Female, % 59.3 61.8
Educational level (% low/
middle/high)
9.2/61.7/29.2 5.7/56.2/38.1
With partner, % 82.9 87.0
Smoking (current), % 37.9 20.4
Alcohol use (last year), % 79.4 80.0
NEO neuroticism 31.7±6.3 28.2±5.5
ABV neuroticism 49.9±25.3 36.7±16.0
ABV somatic complaints 17.9±5.6 15.9±3.8
STAI trait anxiety 34.1±8.8 30.1±5.6
YASR anxious depression 5.0±4.2 3.22±2.7
Beck depression 2.1±2.8 1.11±1.4
For continuous traits, the mean score and SD are listed.
a158 controls are from NESDA.
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visited at home for an additional medical interview, a
fasting blood draw, and collection of urine samples.
Table 1 presents the phenotype data for MDD cases, as a
function of the recruitment setting, and for the total
group. Patients from mental care are on average somewhat
younger, have less often attained a higher educational
level, less often have a spouse/partner and tend to smoke
more heavily. Their profiles on the neuroticism and
depression scales are more unfavourable. From comparing
the total MDD group to the GAIN control group in Table 2,
it may be seen that the control group is slightly older,
better educated, and more often with partner/spouse. With
respect to lifestyle, MDD cases smoke more often (42 vs
20%) but are less often current drinkers (66 vs 80%).
Table 2 shows characteristics of GAIN controls. In
addition, Table 2 provides descriptive statistics, based on
the survey data, for a large group of NTR participants who
are not in GAIN. The subjects in the comparison group
were selected as follows: the subject was not included in
GAIN and was not a family member of a GAIN participant;
was 18 years or older and survey data on personality traits
were available. Only unrelated persons were included in
the comparison group and subjects from the comparison
group were matched on age and sex with the GAIN control
group. Table 2 shows that the GAIN controls are ‘hyper-
controls’: they are better educated, are more often married,
and smoke less often. Their scores on personality traits
related to MDD and on depression indices from the survey
data show a somewhat more favourable profile than the
NTR comparison sample.
Discussion
Progress in unravelling the genetic architecture of multi-
factorial traits such as MDD has been slow. The reasons
have been noted numerous times and include inadequacies
in study design, inappropriate sample-recruitment strategy,
and inadequately powered samples.53 We have tried to
carefully select patients and controls who are at low
liability of developing MDD. Given the sample size of our
study we have 80% power to detect a QTL with genotype
relative risk of 1.33 if the minor allele frequency is at least
0.40 (under the assumption of a log-additive model with a
population prevalence for MDD of 15%54). At 80% power,
the genotype relative risk increases to 1.38 and 1.58 if the
minor allele frequency is 0.25 and 0.10, respectively. The
majority of genetic studies performed to date have had
insufficient power to uncover genetic variants of small
effect.
The genetic basis of liability to MDD and related
disorders has been established through meta-analysis of
data from twin and family studies.13 The meta-analytic
heritability estimate was 37%. We found in the Dutch
population a comparable estimate of heritability, based on
twice the correlation in dizygotic twin and sibling pairs, of
36% for major depression.49 Furthermore, no qualitative
or quantitative sex differences were observed in genetic
architecture, which is a promising starting point for
genetic linkage and association analyses, as it allows
pooling of data from men and women.
The GAIN MDD study will generate GWA data on MDD
cases and controls at low risk of MDD derived from two
large biobank enterprises in the Netherlands. All cases
were diagnosed as having DSM-IV MDD using the CIDI
psychiatric interview. Cases are a highly representative
sample of those affected with this disorder in the Nether-
lands through ascertainment in a variety of health case
settings. The control sample consisted of so-called ‘hyper-
controls’ who were selected from the lower end of the
relevant risk distribution.32 This should increase the power
of the study, compared to the use of unselected control
samples.
One of the major strengths of the NTR and NESDA
studies is that participants are followed longitudinally and
that additional phenotyping and new biological sample
collection are both possible. This means that genome-wide
genotype data can be used in future studies of, for example,
treatment outcomes or of MDD trajectories. Also, to follow
up on the independently replicated genes, detailed
information is available on two major theoretical correlates
of MDD, that is, hypothalamic–pituitary–adrenal axis
(HPA-axis) and autonomic nervous system functioning.
Additional association to such correlated biological pheno-
types would give construct validity to the identified risk
genotypes and point to biological mechanisms. A genotype
that is associated with both depression and increased
sympathetic nervous system activity, for instance, would
suggest that the biological action of the gene may involve
the noradrenergic synapse and its signalling cascade.
NESDA and NTR subjects have provided information on
major life events, and will, in follow-up studies, also be
queried about the occurrence of these events. Longitudinal
data, including the course of MDD, will be available from
NESDA follow-up assessments at 1, 2, 4, 6, and 8 years after
baseline. For NTR participants, up to seven surveys are
available and the eighth survey is scheduled for 2008.
These data can be used for Stage 2 studies, in which gene-
environment interactions are assessed. Further plans for
future use of the GAIN data include data pooling meta-
analytic studies of MDD and other psychiatric disorders
and the detailed analyses of genotypic and phenotypic data
in monozygotic twins who are MDD discordant.
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